BusinessAffimed Provides Update on NK-Cell Immuno-Oncology PlatformBy Nasdaq OMXJan 11, 2017, 1:53 PM UTC
BusinessEyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board membersBy Nasdaq OMXNov 28, 2016, 8:47 PM UTC
BusinessMyoKardia Announces Proposed Public Offering of Common StockBy Nasdaq OMXSep 26, 2016, 8:48 PM UTC
